Novaseq x series 25B reagent kit (300 CYC); novaseq x series 10B reagent kit (300 cycle); nextseq 2000 P3 xleap-SBS reagent kit (100 cycles)
Ended Awarded
- Contract number
- 75N92B25F20019
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $74,628
Award facts
- Contract value 100% obligated
- $74,628.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6810 Chemicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) awarded a delivery order to Illumina, Inc. on September 19, 2025, valued at $74,628.48 with a firm fixed price structure and no set-aside designation. The contract covers the supply of specialized genomic sequencing reagent kits, including NovaSeq X Series 25B and 10B reagent kits (300 cycles) and NextSeq 2000 P3 XLeap-SBS reagent kit (100 cycles), to be delivered by September 18, 2026. The place of performance is Illumina's San Diego, California facility, where the company manufactures these advanced sequencing consumables.
This delivery order supports NIAMSD's scientific research initiatives requiring high-throughput genomic sequencing capabilities for studying arthritis, musculoskeletal diseases, and skin conditions. Illumina, a leading biotechnology manufacturer headquartered in San Diego, specializes in genetic sequencing platforms and has an established history of supplying reagent kits and sequencing instruments across multiple federal agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and Department of Agriculture. The reagent kits specified in this award are consumable products essential for conducting DNA and RNA sequencing operations on Illumina's NextSeq and NovaSeq instrument platforms, enabling the institute's research laboratories to conduct comprehensive genomic analysis of disease-related genetic variations and mechanisms.
Quick answers
Who was awarded contract 75N92B25F20019?
75N92B25F20019 was awarded to Illumina, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 19, 2025.
How much is contract 75N92B25F20019 worth?
The government has obligated $74,628 on 75N92B25F20019.
Is contract 75N92B25F20019 an order under another contract?
Yes. 75N92B25F20019 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N92B25F20019 competed?
The extent of competition for 75N92B25F20019 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award